The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 8th 2024
An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Melanoma Risk for Patients Treated With Biologics Is Inconclusive
May 21st 2020Researchers writing in JAMA Dermatology this week report that patients with inflammatory bowel disease, rheumatoid arthritis, and psoriasis who are treated with biologics may have a "clinically meaningful" increase in melanoma risk, but the jury is still out.
Do bisphosphonates cause atrial fibrillation?
May 20th 2020In this interview with Dr. Kamalan Jeevaratnam, a cardiac electrophysiologist with the Faculty of Health and Medical Sciences at the University of Surrey, we explore whether bisphosphonates are associated with atrial fibrillation. “There are a group of studies that show bisphosphonates are proarrhythmic and a group that show they do not cause any problem,” he said in this interview with Rheumatology Network from his home in London.
The 2020 Treatment Guidelines for Gout
May 19th 2020The American College of Rheumatology has updated its treatment guidelines for gout. The guideline includes 42 treatment recommendations, of which 16 are now strongly recommended. They address standard treat-to-target urate lowering therapy, the use of allopurinol and more. In this slideshow, we highlight the 16 strongest recommendations.
In This Community Health Clinic, the Rheumatologist Is In
May 15th 2020In this week's Rheumatology Network news roundup, we highlight an interview we conducted with Brian LaMoreaux, M.D., M.S., a medical director at Horizon Therapeutics and a volunteer clinical rheumatologist with CommunityHealth in Chicago. In this interview, he shares his experience as a rheumatologist in a community where healthcare is not always easy to come by.
DMARDs Not Linked to Poor Outcomes in SARS-CoV-2 RA Patients
May 13th 2020Data collected by doctors in Italy when the country was hit by COVID-19 should allow rheumatologists to feel more comfortable in advising patients with chronic arthritis to continue taking immunosuppressive targeted therapies. The data show that chronic arthritis patients treated with DMARDs do not seem to be at increased risk of respiratory or life-threatening complications from SARS-CoV-2.
Who should screen for hyperlipidaemia in RA patients? Rheumatologists or primary care physicians?
May 13th 2020Risk factors for cardiovascular disease such as hyperlidipaemia are not being picked up and managed in patients with rheumatology arthritis because it often falls through the gap between rheumatology and primary care provision.
Osteoarthritis Risk Intensifies With Epigenetics
May 13th 2020The risk for osteoarthritis has been linked to a number of genes that are susceptible to epigenetic mediators, shows a new review published in Nature Reviews Rheumatology. The influence of epigenetics on osteoarthritis offers new insights on disease risk.
Review Highlights Urgency for New Lupus Nephritis Research
May 13th 2020Outcomes for patients with lupus nephritis, which can lead to irreversible renal impairment, can be improved with better measures to evaluate risk and detect early disease, along with new treatments, say researchers writing in Nature Reviews Rheumatology.